PDCD1 and neoplasm: Immune checkpoint blockade (ICB), targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis, is an established standard of care in treating many tumours.